Pursuing Cumulative Shareholder Returns Reaching 2 Trillion Won This Year

Celltrion announced that its procedure for the cancellation of approximately 100 billion won worth of treasury shares, which has been promoted to stabilize its share price and enhance shareholder value, was finally reflected on June 4 through a change in listing.


Through this listing change, a total of 488,977 shares have been cancelled, reducing Celltrion’s total number of outstanding shares to approximately 221.63 million shares.

Celltrion Finalizes Cancellation of Approximately 100 Billion Won Worth of Treasury Shares View original image

This treasury share cancellation is the result of executing the recently announced plan to acquire and cancel approximately 100 billion won worth of treasury shares. The company expects this reduction in the number of issued shares will lead to a tangible improvement in earnings per share (EPS) and an increase in per-share value.


Celltrion is not stopping at the cancellation of treasury shares but is also continuing to pursue additional shareholder return policies. The company had previously decided to acquire an additional 100 billion won worth of treasury shares, and the acquisition process is currently underway. If these shares are also cancelled within the year, the cumulative value of treasury shares cancelled in 2026 is expected to reach around 2 trillion won.


In particular, the cumulative amount of treasury shares cancelled over the past three years is about 18.56 million shares, which represents approximately 8.4% of the current total outstanding shares. This is considered the most significant shareholder return policy among domestic pharmaceutical and biotech companies.


Celltrion is also swiftly implementing the comprehensive market response measures announced last month. The company and its largest shareholder are in the process of acquiring a total of 200 billion won worth of shares, with each acquiring 100 billion won, alongside a bonus issue of approximately 10.92 million shares. Employees are also expected to voluntarily participate in stock purchases through the employee stock ownership plan.


Such proactive shareholder return policies are based on strong fundamentals and confidence in future growth. Thanks to the expansion of high-margin new biosimilar sales, Celltrion achieved its best-ever first-quarter results this year, recording 1.145 trillion won in sales and 321.9 billion won in operating profit, thereby demonstrating improved profitability.


Furthermore, Celltrion is steadily pursuing its mid- to long-term growth strategies, including expanding its biosimilar portfolio, developing new drugs, and growing its CDMO business. Based on these efforts, the company aims to achieve its annual targets of 5.3 trillion won in sales and 1.8 trillion won in operating profit this year, thereby strengthening both growth and profitability.



A Celltrion official stated, "The successive cancellation and repurchase of treasury shares reflect our confidence in the company’s strong fundamentals and future growth. We will continue to expand shareholder returns while simultaneously enhancing our core business competitiveness, striving to realize sustainable growth and greater corporate value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing